Abstract
We investigated the role of secondhand smoke (SHS) exposure, independently of diet, in the development of chronic liver disease. Standard diet-fed mice were exposed to SHS (5 h/day, 5 days/week for 4 months). Genome-wide gene expression analysis, together with molecular pathways and gene network analyses, and histological examination for lipid accumulation, inflammation, fibrosis, and glycogen deposition were performed on the liver of SHS-exposed mice and controls, upon termination of exposure and after one-month recovery in clean air. Aberrantly expressed transcripts were found in the liver of SHS-exposed mice both pre- and post-recovery in clean air (n = 473 vs. 222). The persistent deregulated transcripts (n = 210) predominantly affected genes and functional networks involved in lipid metabolism as well as in the regulation of the endoplasmic reticulum where manufacturing of lipids occurs. Significant hepatic fat accumulation (steatosis) was observed in the SHS-exposed mice, which progressively increased as the animals underwent recovery in clean air. Moderate increases in lobular inflammation infiltrates and collagen deposition as well as loss of glycogen were also detectable in the liver of SHS-exposed mice. A more pronounced phenotype, manifested as a disrupted cord-like architecture with foci of necrosis, apoptosis, inflammation, and macrovesicular steatosis, was observed in the liver of SHS-exposed mice post-recovery. The progressive accumulation of hepatic fat and other adverse histological changes in the SHS-exposed mice are highly consistent with the perturbation of key lipid genes and associated pathways in the corresponding animals. Our data support a role for SHS in the genesis and progression of metabolic liver disease through deregulation of genes and molecular pathways and functional networks involved in lipid homeostasis.
Keywords: gene regulation, non-alcoholic fatty liver disease (NAFLD), mouse model, steatosis, tobacco smoke, transcriptome
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver disorders worldwide [1,2]. The incidence of NAFLD is rising in many parts of the world, especially in developed countries [3]. In the United States alone, between 30% and 40% of the adult population is affected with NAFLD [3]. Among children and adolescents, NAFLD is currently the primary form of liver disease; it is estimated that nearly 10% of the US population aged between 2 and 19 has NAFLD [4]. NAFLD has been associated with insulin resistance and metabolic syndrome—a cluster of conditions consisting of high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels—that are key determinants of cardiovascular disease and type 2 diabetes mellitus [1]. Abdominal obesity is a common feature of patients with NAFLD; in obese individuals, the prevalence of NAFLD can exceed 95% [5]. As the epidemic of obesity continues to grow worldwide, so does the prevalence of NAFLD [5].
NAFLD is characterized by the accumulation of fat droplets within the liver cells, a condition known as hepatic ‘steatosis’ [6]. Retention of lipids within the cells reflects an impairment of the normal process of synthesis and elimination of fat, primarily triglycerides [6]. Buildup of excess lipids within the cells manifests as the accumulation of vesicles that can displace the nucleus, disrupt cell constituents and, in severe cases, lead to cell rupture/burst [7]. Non-diagnosed and untreated NAFLD can progress from benign steatosis and fatty liver to more permanent and severe liver injury, including non-alcoholic steatohepatitis (NASH) with inflammation and variable fibrosis, cirrhosis, and eventually hepatocellular carcinoma [8].
Although distinct risk factors for NAFLD have been identified, the exact cause(s) of this disease and the underlying mechanisms of its initiation and progression remain unknown. Accumulating evidence shows that exposure to environmental toxicants, including secondhand smoke (SHS), contributes to the development of NAFLD by promoting mitochondrial dysfunction and oxidative stress within the hepatocytes [9,10,11,12]. Several studies have shown that cigarette smoking is an independent risk factor for the onset of NAFLD [13,14,15,16], and significantly associated with increased intrahepatic fat [17] and advanced liver fibrosis [18,19]. Survey based reports have also shown an association between exposure to SHS and development of NAFLD in children [20,21] and in never-smoking women [22]. A more recent systematic review and meta-analysis established that SHS increases the risk of NAFLD approximately 1.38 times [23]. Animal studies have also provided support for a potential role of SHS in the genesis and progression of NAFLD [24,25,26]. Yuan et al. [26] have shown that subchronic exposure of mice to SHS stimulates hepatic fatty acids synthesis by modulating two key regulators of lipid metabolism, including AMP-activated protein kinase (AMPK) and sterol regulatory element binding protein-1c (SREBP-1c). The SHS-exposed mice in the Yuan et al. study developed hepatic steatosis, which—as the authors inferred—would lead to NAFLD development [26]. De la Monte et al. [25] have demonstrated that A/J mice exposed to SHS exhibit progressive liver injury and steatohepatitis, with impairments in hepatic insulin and insulin-like growth factor (IGF) signaling. Azzalini et al. [24] have shown that nose-only exposure of Zucker ‘obese’ rats to cigarette smoke, mimicking SHS exposure, worsens the histological severity of NAFLD, increases the burden of oxidative stress, and induces hepatocellular apoptosis [24,27].
Although informative, most animal studies investigating the role of SHS exposure in the development of NAFLD have been conducted in rodents fed with high-fat diets that contain cholate, a known cause of liver inflammation and dysfunction [28]. As a result, the role of SHS exposure, independently of diet, in the genesis of NAFLD is not delineated. In addition, the above studies are limited in scope, as they have focused on the analysis of ‘select’ target genes. Therefore, a comprehensive study interrogating the whole transcriptome is needed to establish the global effects of SHS on the regulation of genes that govern NAFLD development. Towards this end, we have constructed the whole hepatic transcriptome in relation to liver histology in ‘standard diet-fed’ mice subchronically exposed to SHS according to our published protocol [29,30,31,32]. More specifically, we have investigated the relationship between global regulation of genes and molecular pathways and gene networks and histological changes indicative of liver injury and hepatic steatosis (i.e., lipid accumulation, inflammation, fibrosis, and glycogen deposition) in the SHS-exposed mice both upon cessation of exposure and after one-month recovery in clean air.
2. Results
2.1. Genome-Wide Gene Expression Changes in the Liver of Secondhand Smoke (SHS)-Exposed Mice
As shown in Figure 1A, subchronic exposure of mice to SHS elicited a significant transcriptomic response, as reflected by the large number of aberrantly expressed transcripts in the SHS-exposed versus control mice. More specifically, there were 473 aberrant transcripts in the SHS-exposed mice relative to age-matched controls (Figure 1A; Table S1). One-month recovery in clean air resulted in slight attenuation of the transcriptional changes in the SHS-exposed mice, although the number of aberrantly expressed transcripts remained considerably high in the exposed mice undergone recovery (i.e., 222 transcripts). There were 210 overlapping aberrant transcripts in the SHS-exposed mice pre- and post-recovery.
Principal component analysis (PCA) and hierarchical clustering analysis in Partek GS® showed clustering of the datasets from mice belonging to the same experimental or control groups, which confirms a uniform gene expression pattern within each experimental/control group (Figure 1B,C). Compiled lists of differentially expressed transcripts in experimental groups relative to controls are shown in Table S1. The lists identify both common and unique deregulated genes in the SHS-exposed mice before and after one-month recovery. Overall, there was a high degree of overlap between differentially expressed genes in the SHS-exposed mice before and after recovery in clean air (Figure 1A; Table S1).
2.2. Modulation of Functional Networks and Biological Pathways in SHS-Exposed Mice
To investigate the lasting effects of SHS, we selected the dataset generated by comparing both the SHS4m and SHS4m+1m recovery groups vs. controls (Set 3; Figure 1A). Of the 210 common transcripts, 201 mapped to known IDs, for a total of 153 unique genes (Table 1). Of the 153 differentially expressed genes (DEGs), 63 (>41%) are known to participate in lipid homeostasis, specifically uptake, synthesis, and accumulation of lipids, as well as fatty acids oxidation and secretion (Table 1). Eighteen of these 63 genes (>28%) are specifically involved in liver steatosis (Figure 2A). To characterize the gene networks and functional pathways associated with the 153 unique genes, we performed gene ontology and functional network analyses, using a combination of Database for Annotation, Visualization and Integrated Discovery (DAVID) and Ingenuity® Pathway Analysis (IPA®). Applying the DAVID annotation clustering analysis tool, we discovered twenty-eight relevant biological clusters. The top functional category with the highest enrichment score consisted of gene sets involved in lipid metabolism (Figure 2B). Based on DAVID analysis, we also detected deregulated genes that are involved in oxidoreductase reactions (Figure 2B). The latter is consistent with SHS being a well-known inducer of reactive oxygen species (ROS) and oxidative stress [33,34]. Other highly enriched categories included genes implicated in endoplasmic reticulum function, circadian regulation of gene expression, lipid biosynthesis, and transcription regulation (Figure 2B).
Table 1.
Expression 1 Log Ratio | ID | D 2 | Symbol 3 | Entrez Gene Name | Location |
---|---|---|---|---|---|
3.543 | 1426037_a_at | D | RGS16 * | regulator of G-protein signaling 16 | Cytoplasm |
3.466 | 1422557_s_at | D | Mt1 | metallothionein 1 | Cytoplasm |
3.26 | 1428942_at | Mt2 | metallothionein 2 | Other | |
3.245 | 1417168_a_at | D | USP2 | ubiquitin specific peptidase 2 | Cytoplasm |
2.943 | 1422257_s_at | D | CYP2B6 | cytochrome P450 family 2 subfamily B member 6 | Cytoplasm |
2.387 | 1442025_a_at | D | ZBTB16 | zinc finger and BTB domain containing 16 | Nucleus |
2.265 | 1418288_at | D | LPIN1 * | lipin 1 | Nucleus |
2.221 | 1427747_a_at | LCN2 | lipocalin 2 | Extracellular Space | |
2.174 | 1428223_at | MFSD2A * | major facilitator superfamily domain containing 2A | Plasma Membrane | |
2.168 | 1443147_at | D | ACOT1 * | acyl-CoA thioesterase 1 | Cytoplasm |
2.095 | 1416125_at | FKBP5 | FK506 binding protein 5 | Nucleus | |
1.956 | 1435188_at | CIART | circadian associated repressor of transcription | Nucleus | |
1.933 | 1425837_a_at | NOCT * | nocturnin | Nucleus | |
1.922 | 1451190_a_at | D | SBK1 | SH3 domain binding kinase 1 | Other |
1.87 | 1428923_at | PPP1R3G | protein phosphatase 1 regulatory subunit 3G | Cytoplasm | |
1.864 | 1451548_at | D | UPP2 | uridine phosphorylase 2 | Cytoplasm |
1.774 | 1460241_a_at | D | ST3GAL5 | ST3 beta-galactoside alpha-2,3-sialyltransferase 5 | Cytoplasm |
1.759 | 1419590_at | Cyp2b13/Cyp2b9 | cytochrome P450, family 2, subfamily b, polypeptide 9 | Cytoplasm | |
1.707 | 1416432_at | PFKFB3 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 | Cytoplasm | |
1.61 | 1429144_at | D | GPCPD1 | glycerophosphocholine phosphodiesterase 1 | Cytoplasm |
1.598 | 1434437_x_at | D | RRM2 | ribonucleotide reductase regulatory subunit M2 | Nucleus |
1.594 | 1416933_at | POR * | cytochrome p450 oxidoreductase | Cytoplasm | |
1.542 | 1439489_at | FFAR4 * | free fatty acid receptor 4 | Plasma Membrane | |
1.542 | 1448162_at | VCAM1 | vascular cell adhesion molecule 1 | Plasma Membrane | |
1.523 | 1429206_at | RHOBTB1 | Rho related BTB domain containing 1 | Other | |
1.518 | 1453023_at | ANKHD1/ANKHD1-EIF4EBP3 | ankyrin repeat and KH domain containing 1 | Other | |
1.493 | 1434473_at | SLC16A5 | solute carrier family 16 member 5 | Plasma Membrane | |
1.492 | 1417761_at | D | APOA4 | apolipoprotein A4 | Extracellular Space |
1.469 | 1417602_at | PER2 | period circadian clock 2 | Nucleus | |
1.45 | 1425824_a_at | PCSK4 | proprotein convertase subtilisin/kexin type 4 | Extracellular Space | |
1.437 | 1448239_at | HMOX1 * | heme oxygenase 1 | Cytoplasm | |
1.433 | 1452416_at | IL6R | interleukin 6 receptor | Plasma Membrane | |
1.418 | 1427473_at | Gstm3 | glutathione S-transferase, mu 3 | Cytoplasm | |
1.403 | 1449851_at | PER1 | period circadian clock 1 | Nucleus | |
1.38 | 1417904_at | DCLRE1A | DNA cross-link repair 1A | Nucleus | |
1.336 | 1450505_a_at | D | FAM134B | family with sequence similarity 134, member B | Cytoplasm |
1.334 | 1440840_at | SLC16A7 | solute carrier family 16 member 7 | Plasma Membrane | |
1.302 | 1423233_at | CEBPD | CCAAT/enhancer binding protein delta | Nucleus | |
1.296 | 1416773_at | WEE1 | WEE1 G2 checkpoint kinase | Nucleus | |
1.279 | 1435459_at | D | FMO2 | flavin containing monooxygenase 2 | Cytoplasm |
1.279 | 1426452_a_at | RAB30 | RAB30, member RAS oncogene family | Cytoplasm | |
1.268 | 1421681_at | D | NRG4 | neuregulin 4 | Extracellular Space |
1.259 | 1435495_at | ADORA1 * | adenosine A1 receptor | Plasma Membrane | |
1.251 | 1426850_a_at | MAP2K6 | mitogen-activated protein kinase kinase 6 | Cytoplasm | |
1.247 | 1421852_at | KCNK5 | potassium two pore domain channel subfamily K member 5 | Plasma Membrane | |
1.246 | 1443870_at | ABCC4 | ATP binding cassette subfamily C member 4 | Plasma Membrane | |
1.242 | 1422230_s_at | CYP2A6 (includes others) | cytochrome P450 family 2 subfamily A member 6 | Cytoplasm | |
1.239 | 1458442_at | AI132709 | expressed sequence AI132709 | Other | |
1.238 | 1424175_at | TEF | TEF, PAR bZIP transcription factor | Nucleus | |
1.231 | 1424744_at | SDS | serine dehydratase | Cytoplasm | |
1.213 | 1434292_at | Snhg11 | small nucleolar RNA host gene 11 | Other | |
1.212 | 1418780_at | CYP39A1 | cytochrome P450 family 39 subfamily A member 1 | Cytoplasm | |
1.207 | 1453410_at | ANGPTL4 | angiopoietin like 4 | Extracellular Space | |
1.199 | 1456156_at | LEPR | leptin receptor | Plasma Membrane | |
1.198 | 1449565_at | Cyp2g1 | cytochrome P450, family 2, subfamily g, polypeptide 1 | Cytoplasm | |
1.198 | 1449498_at | MARCO | macrophage receptor with collagenous structure | Plasma Membrane | |
1.197 | 1428352_at | ARRDC2 | arrestin domain containing 2 | Other | |
1.185 | 1418595_at | PLIN4 | perilipin 4 | Cytoplasm | |
1.178 | 1417042_at | SLC37A4 | solute carrier family 37 member 4 | Cytoplasm | |
1.169 | 1426980_s_at | EPOP | elongin BC and polycomb repressive complex 2 associated protein | Other | |
1.164 | 1445574_at | D | PPARGC1B * | PPARG coactivator 1 beta | Nucleus |
1.162 | 1429809_at | TMTC2 | transmembrane and tetratricopeptide repeat containing 2 | Cytoplasm | |
1.152 | 1455958_s_at | PPTC7 | PTC7 protein phosphatase homolog | Cytoplasm | |
1.151 | 1431339_a_at | D | EFHD2 | EF-hand domain family member D2 | Other |
1.142 | 1428512_at | BHLHB9 | basic helix-loop-helix domain containing, class B, 9 | Cytoplasm | |
1.141 | 1455002_at | D | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | Cytoplasm |
1.133 | 1428926_at | D | FBXO31 | F-box protein 31 | Extracellular Space |
1.123 | 1416286_at | RGS4 | regulator of G-protein signaling 4 | Cytoplasm | |
1.115 | 1432543_a_at | KLF13 | Kruppel like factor 13 | Nucleus | |
1.111 | 1434456_at | RUNDC3B | RUN domain containing 3B | Other | |
1.108 | 1435860_at | SLC5A6 | solute carrier family 5 member 6 | Plasma Membrane | |
1.102 | 1427912_at | CBR3 | carbonyl reductase 3 | Cytoplasm | |
1.098 | 1456395_at | D | PPARGC1A * | PPARG coactivator 1 alpha | Nucleus |
1.091 | 1454799_at | GPAT3 | glycerol-3-phosphate acyltransferase 3 | Cytoplasm | |
1.047 | 1419758_at | ABCB1 | ATP binding cassette subfamily B member 1 | Plasma Membrane | |
1.04 | 1423627_at | NQO1 | NAD(P)H quinone dehydrogenase 1 | Cytoplasm | |
1.036 | 1438211_s_at | DBP | D-box binding PAR bZIP transcription factor | Nucleus | |
1.032 | 1424815_at | GYS2 | glycogen synthase 2 | Cytoplasm | |
1.021 | 1448568_a_at | SLC20A1 | solute carrier family 20 member 1 | Plasma Membrane | |
1.007 | 1428487_s_at | D | COQ10B | coenzyme Q10B | Cytoplasm |
1.007 | 1420772_a_at | TSC22D3 * | TSC22 domain family member 3 | Nucleus | |
1.006 | 1433816_at | SLC25A51 | solute carrier family 25 member 51 | Cytoplasm | |
−1.003 | 1439377_x_at | CDC20 | cell division cycle 20 | Nucleus | |
−1.006 | 1455293_at | LEO1 | LEO1 homolog, Paf1/RNA polymerase II complex component | Nucleus | |
−1.008 | 1431056_a_at | LPL * | lipoprotein lipase | Cytoplasm | |
−1.013 | 1450010_at | HSD17B12 | hydroxysteroid 17-beta dehydrogenase 12 | Cytoplasm | |
−1.022 | 1417292_at | Ifi47 | interferon gamma inducible protein 47 | Cytoplasm | |
−1.022 | 1417792_at | ZNF638 | zinc finger protein 638 | Nucleus | |
−1.027 | 1452445_at | SLC41A2 | solute carrier family 41 member 2 | Plasma Membrane | |
−1.036 | 1448986_x_at | DNASE2 | deoxyribonuclease 2, lysosomal | Cytoplasm | |
−1.037 | 1436931_at | RFX4 | regulatory factor X4 | Nucleus | |
−1.039 | 1450035_a_at | D | PRPF40A | pre-mRNA processing factor 40 homolog A | Nucleus |
−1.04 | 1428022_at | OBP2B * | odorant binding protein 2B | Extracellular Space | |
−1.042 | 1427356_at | FAM89A | family with sequence similarity 89 member A | Other | |
−1.042 | 1424033_at | SRSF7 | serine and arginine rich splicing factor 7 | Nucleus | |
−1.043 | 1457758_at | ENY2 | ENY2, transcription and export complex 2 subunit | Nucleus | |
−1.045 | 1416403_at | ABCB10 | ATP binding cassette subfamily B member 10 | Cytoplasm | |
−1.047 | 1450846_at | BZW1 | basic leucine zipper and W2 domains 1 | Cytoplasm | |
−1.048 | 1438713_at | RASSF8 | Ras association domain family member 8 | Extracellular Space | |
−1.051 | 1433515_s_at | D | ETNK1 | ethanolamine kinase 1 | Cytoplasm |
−1.057 | 1437864_at | ADIPOR2 * | adiponectin receptor 2 | Plasma Membrane | |
−1.057 | 1451122_at | D | IDI1 | isopentenyl-diphosphate delta isomerase 1 | Cytoplasm |
−1.061 | 1425206_a_at | UBE3A | ubiquitin protein ligase E3A | Nucleus | |
−1.073 | 1420379_at | Slco1a1 | solute carrier organic anion transporter family, member 1a1 | Plasma Membrane | |
−1.077 | 1448183_a_at | HIF1A | hypoxia inducible factor 1 alpha subunit | Nucleus | |
−1.085 | 1452030_a_at | HNRNPR | heterogeneous nuclear ribonucleoprotein R | Nucleus | |
−1.085 | 1428372_at | ST5 | suppression of tumorigenicity 5 | Cytoplasm | |
−1.086 | 1450484_a_at | CMPK2 | cytidine/uridine monophosphate kinase 2 | Cytoplasm | |
−1.091 | 1431024_a_at | ARID4B | AT-rich interaction domain 4B | Nucleus | |
−1.108 | 1417832_at | SMC1A | structural maintenance of chromosomes 1A | Nucleus | |
−1.109 | 1424842_a_at | ARHGAP24 | Rho GTPase activating protein 24 | Cytoplasm | |
−1.11 | 1455324_at | D | PLCXD2 | phosphatidylinositol specific phospholipase C X domain containing 2 | Other |
−1.12 | 1426458_at | SLMAP | sarcolemma associated protein | Plasma Membrane | |
−1.128 | 1438269_at | ZBTB38 | zinc finger and BTB domain containing 38 | Nucleus | |
−1.131 | 1449931_at | CPEB4 | cytoplasmic polyadenylation element binding protein 4 | Plasma Membrane | |
−1.136 | 1442537_at | CYP2U1 | cytochrome P450 family 2 subfamily U member 1 | Cytoplasm | |
−1.158 | 1449854_at | NR0B2 | nuclear receptor subfamily 0 group B member 2 | Nucleus | |
−1.16 | 1427574_s_at | SH3D19 | SH3 domain containing 19 | Plasma Membrane | |
−1.165 | 1435775_at | CLOCK | clock circadian regulator | Nucleus | |
−1.169 | 1429772_at | D | PLXNA2 | plexin A2 | Plasma Membrane |
−1.171 | 1437932_a_at | CLDN1 | claudin 1 | Plasma Membrane | |
−1.172 | 1423325_at | PNN | pinin, desmosome associated protein | Plasma Membrane | |
−1.18 | 1447927_at | D | GBP6 | guanylate binding protein family member 6 | Cytoplasm |
−1.205 | 1425099_a_at | ARNTL * | aryl hydrocarbon receptor nuclear translocator like | Nucleus | |
−1.208 | 1444512_at | ARHGAP29 | Rho GTPase activating protein 29 | Cytoplasm | |
−1.238 | 1442367_at | ATP11C | ATPase phospholipid transporting 11C | Plasma Membrane | |
−1.27 | 1417982_at | INSIG2 * | insulin induced gene 2 | Cytoplasm | |
−1.275 | 1427513_at | BC024137 | cDNA sequence BC024137 | Other | |
−1.276 | 1430896_s_at | NUDT7 | nudix hydrolase 7 | Cytoplasm | |
−1.289 | 1450090_at | Zfp101 | zinc finger protein 101 | Nucleus | |
−1.295 | 1449514_at | GRK5 | G protein-coupled receptor kinase 5 | Plasma Membrane | |
−1.325 | 1421092_at | SERPINA12 | serpin family A member 12 | Cytoplasm | |
−1.343 | 1423571_at | S1PR1 | sphingosine-1-phosphate receptor 1 | Plasma Membrane | |
−1.346 | 1420531_at | Hsd3b4 (includes others) | hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 4 | Cytoplasm | |
−1.354 | 1422769_at | D | SYNCRIP | synaptotagmin binding cytoplasmic RNA interacting protein | Nucleus |
−1.379 | 1437581_at | ZNF800 | zinc finger protein 800 | Other | |
−1.395 | 1430785_at | D | SDR9C7 | short chain dehydrogenase/reductase family 9C member 7 | Other |
−1.402 | 1426215_at | DDC * | dopa decarboxylase | Cytoplasm | |
−1.405 | 1426645_at | HSP90AA1 | heat shock protein 90 alpha family class A member 1 | Cytoplasm | |
−1.434 | 1433446_at | D | HMGCS1 | 3-hydroxy-3-methylglutaryl-CoA synthase 1 | Cytoplasm |
−1.472 | 1423397_at | UGT2B28 | UDP glucuronosyltransferase family 2, member B28 | Cytoplasm | |
−1.482 | 1424709_at | D | SC5D | sterol-C5-desaturase | Cytoplasm |
−1.509 | 1450264_a_at | CHKA | choline kinase alpha | Cytoplasm | |
−1.554 | 1438751_at | SLC30A10 | solute carrier family 30 member 10 | Other | |
−1.573 | 1417065_at | EGR1 | early growth response 1 | Nucleus | |
−1.58 | 1433944_at | HECTD2 | HECT domain E3 ubiquitin protein ligase 2 | Cytoplasm | |
−1.622 | 1431817_at | Adh6-ps1 | alcohol dehydrogenase 6 (class V), pseudogene 1 | Other | |
−1.663 | 1439300_at | D | CHIC1 | cysteine rich hydrophobic domain 1 | Plasma Membrane |
−1.666 | 1427347_s_at | D | TUBB2A | tubulin beta 2A class IIa | Cytoplasm |
−1.692 | 1450018_s_at | D | SLC25A30 | solute carrier family 25 member 30 | Cytoplasm |
−1.896 | 1448092_x_at | D | Serpina4-ps1 | serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1 | Other |
−2.034 | 1420722_at | ELOVL3 | ELOVL fatty acid elongase 3 | Cytoplasm | |
−2.382 | 1421447_at | D | ONECUT1 | one cut homeobox 1 | Nucleus |
1 A “positive” (+) fold ratio indicates up-regulation while a “negative” (−) fold ratio indicates down-regulation; 2 D, duplicate transcripts were identified for that gene; 3 genes involved in lipid metabolism (n = 63) are indicated in bold. The asterisk (*) marks genes known to play a role in liver steatosis.
IPA® analysis of the 153 unique DEGs showed disruption of similar gene networks and functional pathways in the SHS-exposed mice, both pre- and post-recovery. As shown in Figure S1, the top impacted networks comprised of genes involved in lipid metabolism and biosynthesis. Other affected gene networks included molecules implicated in behavior and nervous system development and function, cell death and survival, drug metabolism and small molecule biochemistry (Figure S1). The top canonical pathways impacted in the SHS-exposed mice, both pre- and post-recovery, included the lipopolysaccharide (LPS)/IL-1 mediated inhibition of the Retinoid X Receptor (RXR) function (p = 3.11 × 10−6), the adipogenesis pathway (p = 3.97 × 10−6), and the nicotine degradation II pathway (p = 4.98 × 10−6) (Figure 2C). Members of these pathways are known to participate in the negative acute phase response (APR), which down-regulates hepatic genes with crucial physiological roles, in response to liver injury, infection, and/or inflammation. Reduction of key molecules within these pathways ultimately leads to impaired metabolism, transport and/or biosynthesis of lipid, cholesterol, bile acid, and xenobiotics [35].
Next, we used the IPA® Upstream Regulator Analysis tool to identify the upstream regulators that are likely to account for the aberrant expression of the 63 lipid-specific genes. Based on IPA® prediction analysis, we identified the Conserved Helix-Loop-Helix Ubiquitous Kinase (CHUK) as the top master regulator with an activation z-score of 2.376. CHUK is a member of the serine/threonine protein kinase family, and plays an essential role in the NF-κB signaling pathway. The NF-κB pathway is activated by multiple stimuli, including DNA damage [36] and is involved in inflammation, fibrosis and hepatocarcinogenesis [37]. Our prediction analysis shows that CHUK modulates a complex network of upstream regulators (IKBKG, IKBKB, SP1, STAT1, NFKBIA, FOXO3, NF-κB complex, RELA, NFKB1 and TP53), which may work together to elicit the transcriptional changes observed in a subset of lipid-specific genes (25 out of 63 genes). Thirteen of these 25 target genes are presumably under control of the TP53 gene (Figure 3). Four of the TP53-regulated genes, i.e., Rgs16, Lpin1, Hmox1, and Tsc22d3, are known to be involved in liver steatosis (Figure 2A).
2.3. Initiation and Progression of Liver Steatosis in SHS-Exposed Mice
To investigate whether in vivo exposure of mice to SHS causes anomalies in the lipogenic pathways and induces hepatic steatosis, we performed Oil Red O (ORO) staining on liver sections from SHS-exposed mice in comparison to controls. As illustrated in Figure 4A (upper panels), there was a significant increase in fat deposition (steatosis) within the liver cells of SHS-exposed mice, immediately after treatment, as compared to age-matched controls (p = 0.000334). The extent of liver steatosis in the SHS-exposed mice was significantly enhanced after one-month recovery in clean air (SHS4m+1m recovery vs. SHS4m; p = 0.000017 and SHS4m+1m recovery vs. Control 1; p = 0.000276). While reaffirming the steatogenic properties of tobacco smoke on hepatocytes [26,38], these findings show that SHS-induced liver steatosis in vivo is likely to progress and become pervasive. To further determine whether the SHS-induced liver steatosis persisted and/or intensified over prolonged periods of time, we measured fat accumulation in the liver of a subgroup of SHS-exposed mice undergone seven-month recovery in clean air (SHS4m+7m recovery). As shown in Figure 4A (lower panels), extended recovery in clean air resulted in progression of the induced liver steatosis in the SHS-exposed mice (SHS4m+7m recovery vs SHS4m; p < 0.00001). The SHS-exposed mice undergone seven-month recovery also showed significantly higher levels of hepatic fat accumulation than age-matched control mice (SHS4m+7m recovery vs. Control 2; p = 0.000114).
Ogrodnik et al. [39] have recently shown that cellular senescence drives age-dependent hepatic fat accumulation and steatosis through induction of mitochondrial dysfunction, which, in turn, reduces fat metabolism. Consistent with the findings of that study, we observed higher levels of fat accumulation in the liver of control older mice than younger mice (Control 2 vs. Control 1; p = 0.000508). Altogether our data indicate that in vivo exposure of mice to SHS not only initiates liver steatosis but also exacerbates age-dependent progression of hepatic fat deposition.
2.4. Histopathological Evaluation of Liver Injury in SHS-Exposed Mice
Several deregulated genes detected in our dataset (ACOT1, ADIPOR2, ADORA1, EGR1, HMOX1, IL6R, LPIN1, NROB2, and POR) are known to play a crucial role in liver inflammation (Table 1). Three genes in particular, ACOT1, ADIPOR2 and ADORA1, are associated with nonalcoholic steatohepatitis [40,41]. Deregulation of IL6, a potent pleiotropic cytokine, and the hepatic IL6 receptor (IL6R) are important contributors to the immune response and acute inflammation in vivo. To further investigate whether exposure to SHS predisposes mice to other forms of liver injury, including inflammation and/or fibrosis, paraffin-embedded liver sections from experimental and control mice were stained with H&E, Masson’s trichrome and Periodic Acid-Schiff (PAS) stain. As shown in Figure 4B and Figure 5, we observed a mild increase in lobular inflammation infiltrates and collagen deposition (blue areas) in the liver of SHS4m and SHS4m+1m recovery mice, as compared to control mice. Consistent with previous findings [25], a more pronounced phenotype manifested in the liver of mice post-recovery. Liver sections from SHS4m+1m recovery mice showed a disrupted cord-like architecture with foci of necrosis, apoptosis, inflammation and macrovesicular steatosis (Figure 4B, panels c,f). A great variability in the size and nuclear morphology of hepatocytes was also observed in these mice (Figure 4B, panel f). Our data show that exposure to SHS is likely to induce early signs of inflammation and fibrosis, with effects that persist even after termination of exposure. Furthermore, the results obtained by histopathological examination are in good agreement with the gene expression data.
A recent study has shown that lack of liver glycogen causes hepatic insulin resistance and steatosis in mice [42]. To examine whether exposure to SHS affects glycogen metabolism, we also performed PAS staining on liver sections from SHS-exposed mice and controls, before and after recovery. As shown in Figure 5, liver tissues from SHS4m mice displayed prominent loss of glycogen (h, k), while hepatocytes of SHS4m+1m recovery mice and controls showed intense and extensive PAS-positive staining (i, l), indicative of glycogen accumulation. The divergent patterns of glycogen loss/buildup in the liver of SHS-exposed vs. control mice are consistent with body weight gains of the corresponding animals (Figure S2). Whilst mice in the control group gained body weight steadily throughout the sham-exposure and subsequent recovery, the mice in the experimental group showed a nearly flat pattern of body weight gain during the four-month SHS exposure. The SHS-exposed mice, however, started to re-gain weight immediately after the termination of exposure (Figure S2) [29]. In confirmation, we observed up-regulation of glycogen synthase 2 (Gys2) in the SHS4+1m recovery mice relative to controls (Table S1), indicating that synthesis of glycogen is resumed following recovery in clean air.
2.5. Validation of Genome-Wide Gene Expression Data by Reverse Transcription-Quantitative PCR (RT-qPCR)
To validate the genome-wide gene expression data, we randomly selected several up-regulated or down-regulated targets from the 153 gene list (Table 1), and quantified the expression level of each gene by standard Reverse Transcription Quantitative PCR (RT-qPCR). Mean normalized expression levels of all selected genes in the SHS-exposed mice, before and after recovery, relative to age-matched controls are shown in Figure 6A. Consistent with the microarray data, RT-qPCR analysis of total RNA from the liver of SHS-exposed mice pre-recovery showed a ~13-fold increase in relative expression level of the regulator of G-protein signaling 16 gene (Rgs16). The expression level of Rgs16 continued to increase in the SHS-exposed mice after one-month recovery, reaching ~46 times higher than that in age-matched controls (Figure 6A). The regulator of G-protein signaling 16 gene (Rgs16) is a key determinant of lipid metabolism and biosynthesis [43]. RGS16 has been shown to induce hepatic steatosis by inhibiting Gi/Gq-mediated fatty acid oxidation. Transgenic mice specifically expressing RGS16 protein in their hepatocytes have shown to have elevated levels of triglycerides and accumulation of fat deposits in their liver compared to control littermates, while Rgs16 knockout mice have displayed the opposite phenotype [43].
Likewise, over-expression of the Lipin1 (Lpin1) gene, which plays a crucial role in liver metabolism [44,45], was confirmed in the SHS-exposed mice by RT-qPCR analysis. LPIN1 is a bi-functional protein with distinct roles in lipid metabolism, depending on its subcellular localization [46]. In the nucleus, Lpin1 interacts with the peroxisome proliferator-activated receptor α (PPARα) and PPARγ coactivator 1α (PGC-1α) to modulate the expression of genes involved in mitochondrial fatty acid oxidation [44]. In the cytoplasm, LPIN1 functions as a Mg2+-dependent phosphatidate phosphatase enzyme that catalyzes the conversion of phosphatidate to diacylglycerol, a key step in the biosynthesis of triacylglycerol [45]. As shown in Figure 6A, the expression level of Lpin1 was increased in the SHS-exposed mice pre-recovery (2.5-fold) and continued to rise after one month of recovery (~5-fold) relative to age-matched controls. Of significance, both Rgs16 and Lpin1 were identified by IPA® analysis as part of a subset of molecules affecting liver steatosis in the SHS-exposed mice (Figure 2A).
We also confirmed over-expression of the metallothionein 1 (Mt1) gene in the SHS-exposed mice before and after one-month recovery (Figure 6A). Mt1 and its isoform Mt2 belong to a family of small cysteine-rich and heavy metal binding proteins, the metallothioneins (MTs), that are involved in protective stress responses [47]. Synthesis of MTs has been reported to significantly increase due to a variety of stimuli, including oxidative stress, cytotoxicity, irradiation, and DNA damage [47]. Furthermore, we detected SHS-induced up-regulation of the ubiquitin specific peptidase 2 (Usp2) gene and its downstream target, the period circadian clock 1 (Per1) gene, in the SHS-exposed mice vs. controls. The transcription levels of these two genes were significantly elevated in the SHS-exposed mice, both before and after one-month recovery, as compared to age-matched controls (Figure 6A).
Moreover, we verified the SHS-induced down-regulation of other functionally important genes. The hepatocyte nuclear factor 6 (Hnf6/Onecut1) is a member of the one cut family of transcription factors, which modulates expression of numerous genes required for hepatocyte function. Hfn6 is known to be down-regulated during liver injury [48]. The elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 (Elovl3) gene encodes a protein that plays a key role in elongation of long chain fatty acids, thus providing precursors for synthesis of sphingolipids and ceramides [49]. Down-regulation of Onecut1 and Elovl3 transcripts was confirmed in the SHS-exposed mice upon termination of exposure (0.20-fold and 0.17-fold, respectively) and remained persistent in the counterpart mice undergone one-month recovery in clean air (0.78-fold and 0.22-fold, respectively) (Figure 6A).
3. Discussion
First, we analyzed the hepatic transcriptome of SHS-exposed mice, pre- and post-recovery, using genome-wide gene expression analysis followed by functional network and molecular pathway analyses. As shown in Figure 1A and Table S1, SHS-exposure resulted in a significant transcriptomic response, with several hundred differentially expressed transcripts being detectable in the exposed mice immediately after treatment. One-month recovery in clean air only partially mitigated the SHS-induced transcriptional changes as the number of aberrant transcripts in the exposed mice undergone recovery remained substantially high (Figure 1A and Table S1). The persistent transcriptional changes in the SHS-exposed mice predominantly affected genes and functional networks involved in lipid metabolism and biosynthesis as well as in regulation of the endoplasmic reticulum where manufacturing of lipids occurs (Figure 2B, Figure S1 and Table 1). Of the common DEGs in the SHS-exposed mice pre- and post-recovery, 41% are known to modulate lipid metabolism, with 28% being specifically involved in the development of hepatic steatosis (Figure 2A and Table 1).
Upstream Regulator Analysis by IPA® identified a complex network of eleven transcription factors and/or regulators (CHUK, IKBKG, IKBKB, SP1, STAT1, NFKBIA, FOXO3, NF-κB complex, RELA, NFKB1 and TP53) that are likely to account for the observed deregulation of lipid metabolism-specific genes and associated pathways in the SHS-exposed mice (Figure 3). This network includes NF-κB, whose activation in non-parenchymal cells is generally recognized to promote inflammation, fibrosis and hepatocarcinogenesis [37]. Of significance is also the predicted activation of TP53, a preferential target of DNA-damaging agents, such as tobacco smoke carcinogens [30,50,51], and a key regulator in fatty liver and insulin resistance [52]. TP53 interacts with the NK-kB complex, and crosstalk between the TP53 and NF-kB transcription factors has been shown to play a pivotal role in determining the cellular response to certain stimuli, e.g., DNA damage [53]. The predicted activation of TP53 is in accordance with the expression status of several downstream lipid targets found in the SHS-exposed mice, both before and after recovery in clean air (Figure 3).
A novel finding of our study is the SHS-induced up-regulation of Rgs16 and Lpin1, two TP53 downstream effectors with crucial roles in lipid metabolism and liver steatosis (Figure 2A). RGS16 is known to be induced by doxorubicin in cells expressing wild-type p53 [54]. In normal lung fibroblasts, RGS16 is transcriptionally activated by exogenous expression of p53, either individually or in combination with retinoblastoma 1 [55]. TP53 can also up-regulate the expression of Lpin1 via three p53 binding sites located on the first intron of the gene [56]. Whole body γ-irradiation of wild-type p53 mice, but not p53−/− mice, has been shown to cause up-regulation of Lpin 1 in several organs, with a pattern of expression resembling that of typical p53-responsive genes, including the p21WAF1 gene [56]. In addition to being bona fide targets of p53, Rgs16 and Lpn1 contain potential sterol regulatory element (SRE) binding sites for SREBP-1, a key regulator of lipid metabolism under the negative control of AMPK [57].
A growing number of studies has shown a ‘noncanonical’ role for p53 in modulating lipid metabolism by either transcriptional regulation of target molecules involved in fatty acid synthesis and oxidation and lipid droplet formation or via direct protein-protein interactions [58,59,60,61]. Based on our results, we propose a model in which SHS induces TP53 via the DNA-damage response pathway, the ataxia–telangiectasia mutated/ataxia–telangiectasia and Rad3 related (ATM/ATR) kinase pathway). Active TP53, in turn, transcriptionally activates Rgs16 and Lpin1, and most likely additional steatogenic genes in a tissue-specific context, ultimately leading to liver steatosis (Figure 6B). Alternatively, SHS can cause mutations in the TP53 gene, and gain-of-function mutant forms of TP53 have been found to enhance fatty acid synthesis by inhibitory interaction with AMPKα, and consequent activation of SREBP-1 (Figure 6B) [60]. In turn, SREBP-1 can transcriptionally activate Rgs16 and Lpin1 through the SRE binding sites located on these genes. Yuan et al. have previously reported inactivation of AMPK and activation of SREBP-1c concurrent with hepatic lipid accumulation in mice fed with high-fat-diet and exposed to SHS [26]. Altogether, the deregulation of Rgs16 and Lpin1 in the SHS-exposed mice found in our study may provide novel insights into the interplay of carcinogen exposure, TP53-dependent response, and metabolic liver disease. Work in our laboratory is currently underway to further investigate the herein proposed model of SHS-induced hepatic steatosis via the TP53 pathway.
Lastly, the perturbation of key lipid genes in the SHS-exposed mice, which persisted after recovery in clean air, is highly consistent with the progressive accumulation of fat and other adverse histological changes observed in the liver of corresponding animals (Figure 4 and Figure 5). As shown in Figure 4A, the extent of fat accumulation in the liver of SHS-exposed mice progressively increased after recovery time in clean air (Figure 4A). Furthermore, SHS-exposed mice undergone recovery displayed more pronounced signs of liver injury, including disorganized lobular architecture, foci of inflammation, necrosis, and variable fibrosis (Figure 4B and Figure 5). One possible explanation for this observation is that the cascade of events triggered by exposure to SHS can further progress, even in the absence of SHS, and cause potentially irreversible liver injury. According to the ‘multiple-hit’ hypothesis, multiple events are required to promote NAFLD initiation and progression. Based on our results, SHS-induced disruption of lipid homeostasis with consequent steatosis may constitute the first hit. Additional factors (metabolic, environmental, genetic and/or epigenetic mechanisms) can further exacerbate liver injury mostly through modulation of pathways involved in mitochondrial dysfunction, oxidative stress, fatty acid biosynthesis, and inflammation, thus, leading to more severe forms of NAFLD. In other words, the first hit (SHS-induced liver steatosis) can increase the susceptibility to subsequent hits, and this could explain why we observed more pronounced effects in SHS4m+1m recovery mice. Future follow up studies are needed to investigate the likelihood of the above scenarios in human populations.
4. Materials and Methods
4.1. Animal Care and Maintenance
This study was conducted in accordance with the recommendations described in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and all efforts were made to minimize animal suffering [62]. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the City of Hope (Protocol Number: 09012, 07 January 2009). All mice were fed a standard diet consisting, at a caloric level, of 25% proteins, 13% fat, and 62% carbohydrates (PicoLab® Rodent Diet 20, PMI Nutrition International, LLC., Brentwood, MO, USA). At all times, including the exposure phase and recovery period, the mice had access to food and water ad libitum.
4.2. Smoking Machine and SHS Exposure
The smoking machine and exposure protocol have been described in detail in [29,30]. Briefly, SHS was generated using a custom-made TE-10 smoking machine (Teague Enterprises, Woodland, CA, USA). The TE-10 smoking machine is a microprocessor-controlled unit that can generate mainstream smoke, sidestream smoke, or a combination of the two. The machine was programmed to burn 3R4F Reference Kentucky cigarettes (Tobacco Research Institute, University of Kentucky, Lexington, KY, USA), and produce a mixture of sidestream smoke (89%) and mainstream smoke (11%). This formulation is conventionally used to mimic SHS for in vivo exposure and is representative of the SHS inhaled by humans in real life [32,63,64].
At the outset, all experimental mice underwent an acclimatization period during which they were gradually exposed ‘whole body’ to incremental doses of SHS. Following the acclimatization period, the mice were maintained on a SHS exposure regimen, which included 5 h per day, 5 days per week, and four-month whole body exposure to SHS, produced by continuous burning of 7–9 cigarettes. The average concentrations of total suspended particulate (TSP) in the exposure chambers were 233.0 ±15.4 mg/m3 at any given time during the four-month SHS exposure. The respective average TSP concentrations correspond to SHS generated through continuous smoking of 8.0 ± 0.5 cigarettes, at any given time during the four-month SHS exposure [29].
We note that whole body smoke exposure in rodents may result in residual transdermal and gastrointestinal absorption of smoke particles consequent to grooming [30]. However, ‘nose-only’ exposure can cause stress and discomfort for the animals, which would be pronounced in long-term studies, such as the present one. Therefore, we chose whole body exposure of mice to SHS based on tolerability and practicality of this approach and its compatibility with our study design. In addition, whole body smoke exposure in mice recapitulates real-life human exposure to SHS [30].
4.3. Study Design
Adult male mice (6–8 weeks old), on a C57BL/6 genetic background, were randomly assigned to two groups, including (1) ‘experimental’ (SHS exposure) and (2) ‘control’ (sham-treatment in clean air). The experimental group was divided in two subgroups (5 mice per subgroup), including four-month SHS exposure (SHS4m) and four-month SHS exposure plus one-month recovery in clean air (SHS4m+1m recovery). Age-matched control mice were similarly subdivided in sham-treatment subgroups, with and without recovery (5 mice per subgroup). The sham-treated mice were exposed to filtered high-efficiency particulate air (HEPA) in lieu of SHS, as described previously [29,30,31,32]. At the end of all experiments, the SHS-exposed and control mice were euthanized by CO2 asphyxiation and various tissues and organs, including the liver, were harvested and kept at −80 °C until further analysis. We note that based on life span, four-month SHS exposure in mice is equivalent to approximately 12 years human exposure to SHS, which is a realistic and biologically relevant exposure scenario in real-life. In our previously published studies [29,30,31,32,65,66], we have also verified that four-month SHS exposure is sufficient to elicit significant genotoxic, epigenetic, and transcriptomic responses in various organs and tissues of male C57BL/6 mice. We have also confirmed that five mice per group are sufficient to yield, at a minimum, a study power of 1 − β = 80%, and statistically significant results at p < 0.05.
4.4. Genome-Wide Gene Expression Analysis
To construct the hepatic transcriptome in SHS-exposed mice, we used the GeneChip® Mouse Genome 430 2.0 Array (originally from Affymetrix Inc., Santa Clara, CA, USA; currently Thermo Fisher Scientific, Waltham, MA, USA). This microarray platform enables interrogation of over 39,000 transcripts and variants from more than 34,000 well-characterized mouse genes. Briefly, total RNA was isolated from liver tissues of SHS-exposed mice and controls, using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Synthesis of double-stranded cDNA from total RNA, fragmentation, hybridization, staining, and microarray scanning were performed according to the manufacturer’s instructions (Affymetrix Inc.). Quality control evaluation and processing and analysis of expression data were performed using the Affymetrix Expression Console™ software (Affymetrix Inc.). The Bioconductor package ‘ArrayTools’ was used to identify differentially expressed genes in experimental groups relative to controls, as described previously [67]. To establish gene expression trends within each experimental group, significant gene lists were examined by hierarchical clustering analysis and principal component analysis (PCA) using the Partek® Genomics Suite® software (Partek Incorporated, St. Louis, MO, USA). Raw microarray data have been deposited in the Gene Expression Omnibus database at NCBI (accession number: GSE139440; htttp://www.ncbi.nlm.nih.gov/geo/).
4.5. Gene Ontology and Canonical Pathways Analysis
Gene ontology (GO) analysis was performed using a combination of the Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Tool v.6.8 [68] and the Ingenuity® Pathway Analysis (IPA®) v.9 tool (QIAGEN Bioinformatics, Redwood City, CA, USA; www.qiagenbioinformatics.com). The Functional Clustering Analysis tool in DAVID was used to group together similar annotation terms for all categories, while functional identification of gene networks, canonical pathways, and upstream regulators was done by IPA®.
4.6. Histological Examination
For histological visualization of fat content and neutral triglycerides, we performed Oil Red O (ORO) staining on liver sections prepared from SHS-exposed mice and controls, according to a published protocol [69]. Bright-field images were captured with an Olympus microscope (Camera Model DP27, Tokyo, Japan), at several magnifications, using the CellSens Standard software (Olympus, Tokyo, Japan). Quantification of lipid droplets in the ORO-stained slides was achieved by measuring the area occupied by red pixels, in ImageJ software (https://imagej.nih.gov/ij/), as described previously [69].
Paraffin-embedded liver sections were stained with hematoxylin and eosin (H&E), Masson’s trichrome and Periodic Acid-Schiff (PAS) stain according to standard procedures [70,71]. Images were acquired with the Philips IntelliSite Pathology Solutions (PIPS) system.
4.7. Reverse Transcription Quantitative PCR (RT-qPCR)
For validation purposes, we used a standard RT-qPCR protocol [66] to determine the expression level of single up-regulated or down-regulated genes identified by microarray analysis. Detailed descriptions for RT-qPCR method are available in Supplementary Material.
5. Conclusions
We have demonstrated, for the first time, that subchronic exposure of mice to SHS, independently of diet, induces liver steatosis by modulating genes and functional pathways involved in lipid metabolism. Our findings underscore how an environmental carcinogen, such as SHS, in addition to cancer-causing effects, may contribute to other adverse health consequences, specifically metabolic liver disease.
Acknowledgments
Work of the authors was supported by grants from Tobacco-Related Disease Research Program (25IP-0001 and 26IP-0051) awarded to ST and grants from National Institute of Dental and Craniofacial Research (1R01DE026043) and Tobacco-Related Disease Research Program (26IR-0015) awarded to AB. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit for publication.
Abbreviations
AMPK | AMP-activated kinase |
APR | Acute Phase Response |
CHUK | Component of inhibitor of nuclear factor kappa B kinase complex |
DAVID | Database for Annotation, Visualization and Integrated Discovery |
DEGs | Differentially expressed genes |
Elovl3 | Elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 |
FOXO3 | Forkhead box O3 |
GO | Gene Ontology |
Gapdh | Glyceraldehyde-3-phosphate dehydrogenase |
H&E | hematoxylin and eosin |
Hmox1 | Heme oxygenase 1 |
Hnf6/Onecut1 | Hepatocyte nuclear factor 6 |
HEPA | High-efficiency particulate air |
IPA | Ingenuity Pathway Analysis |
IKBKB | Inhibitor of nuclear factor kappa B kinase subunit beta |
IKBKG | Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
IACUC | Institutional Animal Care and Use Committee |
IGF | Insulin-like growth factor |
IL-1 | interleukin-1 |
Lpin1 | Lipin 1 |
LPS | lipopolysaccharide |
NAFLD | Non-alcoholic fatty liver disease |
MTs | Metallothioneins |
Mt1 | Metallothionein 1 |
NFKBIA | NFKB inhibitor alpha |
NF-κB | Nuclear factor kappa B |
NFKB1 | Nuclear factor kappa B subunit 1 |
ORO | Oil Red O |
PAS | Periodic Acid-Schiff |
PCA | principal component analysis |
PPARα | Peroxisome proliferator-activated receptor α |
PGC-1α | PPARγ coactivator 1α |
RELA | RELA proto-oncogene |
RXR | NF-κB subunit Retinoid X Receptor |
Per1 | Period circadian clock 1 |
SHS | Secondhand smoke |
ROS | Reactive oxygen species |
Rgs16 | Regulator of G-protein signaling 16 |
RT-qPCR | Reverse transcription quantitative polymerase chain reaction |
SP1 | Sp1 transcription factor |
STAT1 | Signal transducer and activator of transcription 1 |
SREBPs | Sterol regulatory elements binding sites for proteins |
SREBP-1c | Sterol regulatory element binding protein-1c |
TSP | Total suspended particulate |
Tsc22d3 | TSC22 domain family, member 3 |
TP53 | Tumor protein p53 |
Usp2 | Ubiquitin specific peptidase 2 |
Supplementary Materials
The following are available online at https://www.mdpi.com/1422-0067/21/4/1296/s1.
Author Contributions
S.T. & A.B.: Conceived and designed the study; S.T., J.-I.Y. & A.B.: Performed experiments and collected data; S.T. & A.B.: Analyzed data and interpreted the results; S.T. & A.B.: Wrote the manuscript. All authors have read and agreed to the published version of the manuscript.
Conflicts of Interest
All authors declare no conflict of interest.
References
- 1.Byrne C.D., Targher G. NAFLD: A multisystem disease. J. Hepatol. 2015;62:S47–S64. doi: 10.1016/j.jhep.2014.12.012. [DOI] [PubMed] [Google Scholar]
- 2.Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. doi: 10.1002/hep.28431. [DOI] [PubMed] [Google Scholar]
- 3.Neuschwander-Tetri B.A. Fatty liver and the metabolic syndrome. Curr. Opin. Gastroenterol. 2007;23:193–198. doi: 10.1097/MOG.0b013e32801421a9. [DOI] [PubMed] [Google Scholar]
- 4.Takahashi Y., Fukusato T. Pediatric nonalcoholic fatty liver disease: Overview with emphasis on histology. World J. Gastroenterol. 2010;16:5280–5285. doi: 10.3748/wjg.v16.i42.5280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ofosu A., Ramai D., Reddy M. Non-alcoholic fatty liver disease: Controlling an emerging epidemic, challenges, and future directions. Ann. Gastroenterol. 2018;31:288–295. doi: 10.20524/aog.2018.0240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Kawano Y., Cohen D.E. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J. Gastroenterol. 2013;48:434–441. doi: 10.1007/s00535-013-0758-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Mashek D.G., Khan S.A., Sathyanarayan A., Ploeger J.M., Franklin M.P. Hepatic lipid droplet biology: Getting to the root of fatty liver. Hepatology. 2015;62:964–967. doi: 10.1002/hep.27839. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zoller H., Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism. 2016;65:1151–1160. doi: 10.1016/j.metabol.2016.01.010. [DOI] [PubMed] [Google Scholar]
- 9.Armstrong L.E., Guo G.L. Understanding Environmental Contaminants’ Direct Effects on Non-alcoholic Fatty Liver Disease Progression. Curr. Environ. Health Rep. 2019;6:95–104. doi: 10.1007/s40572-019-00231-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Klaunig J.E., Li X., Wang Z. Role of xenobiotics in the induction and progression of fatty liver disease. Toxicol. Res. (Camb.) 2018;7:664–680. doi: 10.1039/C7TX00326A. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.VoPham T. Environmental risk factors for liver cancer and nonalcoholic fatty liver disease. Curr. Epidemiol. Rep. 2019;6:50–66. doi: 10.1007/s40471-019-0183-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Tommasi S., Besaratinia A. DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease. Int. J. Environ. Res. Public Health. 2019;16:2791. doi: 10.3390/ijerph16152791. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Hamabe A., Uto H., Imamura Y., Kusano K., Mawatari S., Kumagai K., Kure T., Tamai T., Moriuchi A., Sakiyama T., et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J. Gastroenterol. 2011;46:769–778. doi: 10.1007/s00535-011-0376-z. [DOI] [PubMed] [Google Scholar]
- 14.Chang Y., Jung H.S., Yun K.E., Cho J., Cho Y.K., Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am. J. Gastroenterol. 2013;108:1861–1868. doi: 10.1038/ajg.2013.349. [DOI] [PubMed] [Google Scholar]
- 15.Oniki K., Hori M., Saruwatari J., Morita K., Kajiwara A., Sakata M., Mihara S., Ogata Y., Nakagawa K. Interactive effects of smoking and glutathione S-transferase polymorphisms on the development of non-alcoholic fatty liver disease. Toxicol. Lett. 2013;220:143–149. doi: 10.1016/j.toxlet.2013.04.019. [DOI] [PubMed] [Google Scholar]
- 16.Okamoto M., Miyake T., Kitai K., Furukawa S., Yamamoto S., Senba H., Kanzaki S., Deguchi A., Koizumi M., Ishihara T., et al. Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: A longitudinal cohort study. PLoS ONE. 2018;13:e0195147. doi: 10.1371/journal.pone.0195147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kato A., Li Y., Ota A., Naito H., Yamada H., Nihashi T., Hotta Y., Chiang C., Hirakawa Y., Aoyama A., et al. Smoking results in accumulation of ectopic fat in the liver. Diabetes Metab. Syndr. Obes. 2019;12:1075–1080. doi: 10.2147/DMSO.S212495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Zein C.O., Unalp A., Colvin R., Liu Y.C., McCullough A.J. Nonalcoholic Steatohepatitis Clinical Research Network. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J. Hepatol. 2011;54:753–759. doi: 10.1016/j.jhep.2010.07.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Huang C.W., Horng C.T., Huang C.Y., Cho T.H., Tsai Y.C., Chen L.J., Hsu T.C. Tzang BS Secondhand smoke induces hepatic apoptosis and fibrosis in hamster fetus. Hum. Exp. Toxicol. 2016;35:1005–1015. doi: 10.1177/0960327115617228. [DOI] [PubMed] [Google Scholar]
- 20.Al-Sayed E.M., Ibrahim K.S. Second-hand tobacco smoke and children. Toxicol. Ind. Health. 2014;30:635–644. doi: 10.1177/0748233712462473. [DOI] [PubMed] [Google Scholar]
- 21.Lin C., Rountree C.B., Methratta S., LaRusso S., Kunselman A.R., Spanier A.J. Secondhand tobacco exposure is associated with nonalcoholic fatty liver disease in children. Environ. Res. 2014;132:264–268. doi: 10.1016/j.envres.2014.04.005. [DOI] [PubMed] [Google Scholar]
- 22.Liu Y., Dai M., Bi Y., Xu M., Xu Y., Li M., Wang T., Huang F., Xu B., Zhang J., et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): A population-based study in China. J. Epidemiol. 2013;23:115–121. doi: 10.2188/jea.JE20120067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Rezayat A.A., Moghadam M.D., Nour M.G., Shirazinia M., Ghodsi H., Rouhbakhsh Zahmatkesh M.R., Noghabi M.T., Hoseini B., Rezayat K.A. Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis. SAGE Open Med. 2018;6:2050312117745223. doi: 10.1177/2050312117745223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Azzalini L., Ferrer E., Ramalho L.N., Moreno M., Domínguez M., Colmenero J., Peinado V.I., Barberà J.A., Arroyo V., Ginès P., et al. Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology. 2010;51:1567–1576. doi: 10.1002/hep.23516. [DOI] [PubMed] [Google Scholar]
- 25.De la Monte S.M., Tong M., Agarwal A.R., Cadenas E. Tobacco Smoke-Induced Hepatic Injury with Steatosis, Inflammation, and Impairments in Insulin and Insulin-Like Growth Factor Signaling. J. Clin. Exp. Pathol. 2016;6:269. doi: 10.4172/2161-0681.1000269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Yuan H., Shyy J.Y., Martins-Green M. Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1. J. Hepatol. 2009;51:535–547. doi: 10.1016/j.jhep.2009.03.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Zein C.O. Clearing the smoke in chronic liver diseases. Hepatology. 2010;51:1487–1490. doi: 10.1002/hep.23694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Yuan H., Wong L.S., Bhattacharya M., Ma C., Zafarani M., Yao M., Schneider M., Pitas R.E., Martins-Green M. The effects of second-hand smoke on biological processes important in atherogenesis. BMC Cardiovasc. Disord. 2007;7:1. doi: 10.1186/1471-2261-7-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Kim S.I., Arlt V.M., Yoon J.I., Cole K.J., Pfeifer G.P., Phillips D.H., Besaratinia A. Whole body exposure of mice to secondhand smoke induces dose-dependent and persistent promutagenic DNA adducts in the lung. Mutat. Res. 2011;716:92–98. doi: 10.1016/j.mrfmmm.2011.08.008. [DOI] [PubMed] [Google Scholar]
- 30.Kim S.I., Yoon J.I., Tommasi S., Besaratinia A. New experimental data linking secondhand smoke exposure to lung cancer in nonsmokers. FASEB J. 2012;26:1845–1854. doi: 10.1096/fj.11-199984. [DOI] [PubMed] [Google Scholar]
- 31.Tommasi S., Zheng A., Yoon J.I., Li A.X., Wu X., Besaratinia A. Whole DNA methylome profiling in mice exposed to secondhand smoke. Epigenetics. 2012;7:1302–1314. doi: 10.4161/epi.22453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Tommasi S., Zheng A., Besaratinia A. Exposure of mice to secondhand smoke elicits both transient and long-lasting transcriptional changes in cancer-related functional networks. Int. J. Cancer. 2015;136:2253–2263. doi: 10.1002/ijc.29284. [DOI] [PubMed] [Google Scholar]
- 33.Sundar I.K., Yao H., Rahman I. Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid. Redox Signal. 2013;18:1956–1971. doi: 10.1089/ars.2012.4863. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Izzotti A., Pulliero A. Molecular damage and lung tumors in cigarette smoke-exposed mice. Ann. N. Y. Acad. Sci. 2015;1340:75–83. doi: 10.1111/nyas.12697. [DOI] [PubMed] [Google Scholar]
- 35.Strnad P., Tacke F., Koch A., Trautwein C. Liver—Guardian, modifier and target of sepsis. Nat. Rev. Gastroenterol. Hepatol. 2017;14:55–66. doi: 10.1038/nrgastro.2016.168. [DOI] [PubMed] [Google Scholar]
- 36.Huang W.C., Hung M.C. Beyond NF-kappaB activation: Nuclear functions of IkappaB kinase alpha. J. Biomed. Sci. 2013;20:3. doi: 10.1186/1423-0127-20-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Luedde T., Schwabe R.F. NF-kappaB in the liver—Linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011;8:108–118. doi: 10.1038/nrgastro.2010.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Mallat A., Lotersztajn S. Cigarette smoke exposure: A novel cofactor of NAFLD progression? J. Hepatol. 2009;51:430–432. doi: 10.1016/j.jhep.2009.05.021. [DOI] [PubMed] [Google Scholar]
- 39.Ogrodnik M., Miwa S., Tchkonia T., Tiniakos D., Wilson C.L., Lahat A., Day C.P., Burt A., Palmer A., Anstee Q.M., et al. Cellular senescence drives age-dependent hepatic steatosis. Nat. Commun. 2017;8:15691. doi: 10.1038/ncomms15691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., Ebenbichler C.F., Patsch J.R., Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117–121. doi: 10.1136/gut.2003.037010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Karczewski K.J., Dudley J.T., Kukurba K.R., Chen R., Butte A.J., Montgomery S.B., Snyder M. Systematic functional regulatory assessment of disease-associated variants. Proc. Natl. Acad. Sci. USA. 2013;110:9607–9612. doi: 10.1073/pnas.1219099110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Irimia J.M., Meyer C.M., Segvich D.M., Surendran S., DePaoli-Roach A.A., Morral N., Roach P.J. Lack of liver glycogen causes hepatic insulin resistance and steatosis in mice. J. Biol. Chem. 2017;292:10455–10464. doi: 10.1074/jbc.M117.786525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Pashkov V., Huang J., Parameswara V.K., Kedzierski W., Kurrasch D.M., Tall G.G., Esser V., Gerard R.D., Uyeda K., Towle H.C., et al. Regulator of G protein signaling (RGS16) inhibits hepatic fatty acid oxidation in a carbohydrate response element-binding protein (ChREBP)-dependent manner. J. Biol. Chem. 2011;286:15116–15125. doi: 10.1074/jbc.M110.216234. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Finck B.N., Gropler M.C., Chen Z., Leone T.C., Croce M.A., Harris T.E., Lawrence J.C., Jr., Kelly D.P. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 2006;4:199–210. doi: 10.1016/j.cmet.2006.08.005. [DOI] [PubMed] [Google Scholar]
- 45.Han G.S., Wu W.I., Carman G.M. The Saccharomyces cerevisiae Lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme. J. Biol. Chem. 2006;281:9210–9218. doi: 10.1074/jbc.M600425200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Bi L., Jiang Z., Zhou J. The role of lipin-1 in the pathogenesis of alcoholic fatty liver. Alcohol. Alcohol. 2015;50:146–151. doi: 10.1093/alcalc/agu102. [DOI] [PubMed] [Google Scholar]
- 47.Ruttkay-Nedecky B., Nejdl L., Gumulec J., Zitka O., Masarik M., Eckschlager T., Stiborova M., Adam V., Kizek R. The role of metallothionein in oxidative stress. Int. J. Mol. Sci. 2013;14:6044–6066. doi: 10.3390/ijms14036044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Wang M., Chen M., Zheng G., Dillard B., Tallarico M., Ortiz Z., Holterman A.X. Transcriptional activation by growth hormone of HNF-6-regulated hepatic genes, a potential mechanism for improved liver repair during biliary injury in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2008;295:G357–G366. doi: 10.1152/ajpgi.00581.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Zadravec D., Brolinson A., Fisher R.M., Carneheim C., Csikasz R.I., Bertrand-Michel J., Borén J., Guillou H., Rudling M., Jacobsson A. Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity. FASEB J. 2010;24:4366–4377. doi: 10.1096/fj.09-152298. [DOI] [PubMed] [Google Scholar]
- 50.Besaratinia A., Pfeifer G.P. Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. FASEB J. 2010;24:2612–2619. doi: 10.1096/fj.10-157263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Hecht S.S. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer. 2003;3:733–744. doi: 10.1038/nrc1190. [DOI] [PubMed] [Google Scholar]
- 52.Huang S., Sun C., Hou Y., Tang Y., Zhu Z., Zhang Z., Zhang Y., Wang L., Zhao Q., Chen M.G., et al. A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Sci. Rep. 2018;8:7630. doi: 10.1038/s41598-018-25658-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Tergaonkar V., Perkins N.D. p53 and NF-kappaB crosstalk: IKKalpha tips the balance. Mol. Cell. 2007;26:158–159. doi: 10.1016/j.molcel.2007.04.006. [DOI] [PubMed] [Google Scholar]
- 54.Buckbinder L., Velasco-Miguel S., Chen Y., Xu N., Talbott R., Gelbert L., Gao J., Seizinger B.R., Gutkind J.S., Kley N. The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc. Natl. Acad. Sci. USA. 1997;94:7868–7872. doi: 10.1073/pnas.94.15.7868. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Carper M.B., Denvir J., Boskovic G., Primerano D.A., Claudio P.P. RGS16, a novel p53 and pRb cross-talk candidate inhibits migration and invasion of pancreatic cancer cells. Genes Cancer. 2014;5:420–435. doi: 10.18632/genesandcancer.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Assaily W., Rubinger D.A., Wheaton K., Lin Y., Ma W., Xuan W., Brown-Endres L., Tsuchihara K., Mak T.W., Benchimol S. ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol. Cell. 2011;44:491–501. doi: 10.1016/j.molcel.2011.08.038. [DOI] [PubMed] [Google Scholar]
- 57.Seo Y.K., Chong H.K., Infante A.M., Im S.-S., Xie X., Osborne T.F. Genome-wide analysis of SREBP-1 binding in mouse liver chromatin reveals a preference for promoter proximal binding to a new motif. Proc. Natl. Acad. Sci. USA. 2009;106:13765–13769. doi: 10.1073/pnas.0904246106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Goldstein I., Ezra O., Rivlin N., Molchadsky A., Madar S., Goldfinger N., Rotter V. p53, a novel regulator of lipid metabolism pathways. J. Hepatol. 2012;56:656–662. doi: 10.1016/j.jhep.2011.08.022. [DOI] [PubMed] [Google Scholar]
- 59.Goldstein I., Rotter V. Regulation of lipid metabolism by p53—Fighting two villains with one sword. Trends Endocrinol. Metab. 2012;23:567–575. doi: 10.1016/j.tem.2012.06.007. [DOI] [PubMed] [Google Scholar]
- 60.Parrales A., Iwakuma T. p53 as a Regulator of Lipid Metabolism in Cancer. Int. J. Mol. Sci. 2016;17:2074. doi: 10.3390/ijms17122074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Berkers C.R., Maddocks O.D., Cheung E.C., Mor I., Vousden K.H. Metabolic regulation by p53 family members. Cell Metab. 2013;18:617–633. doi: 10.1016/j.cmet.2013.06.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Council N.R. Guide for the Care and Use of Laboratory Animals. 8th ed. The National Academies Press; Washington, DC, USA: 2011. [Google Scholar]
- 63.D’Agostini F., Izzotti A., Balansky R., Zanesi N., Croce C.M., De Flora S. Early loss of Fhit in the respiratory tract of rodents exposed to environmental cigarette smoke. Cancer Res. 2006;66:3936–3941. doi: 10.1158/0008-5472.CAN-05-3666. [DOI] [PubMed] [Google Scholar]
- 64.Besaratinia A., Pfeifer G.P. Second-hand smoke and human lung cancer. Lancet Oncol. 2008;9:657–666. doi: 10.1016/S1470-2045(08)70172-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Tommasi S., Zheng A., Yoon J.I., Besaratinia A. Epigenetic targeting of the Nanog pathway and signaling networks during chemical carcinogenesis. Carcinogenesis. 2014;35:1726–1736. doi: 10.1093/carcin/bgu026. [DOI] [PubMed] [Google Scholar]
- 66.Tommasi S., Zheng A., Besaratinia A. Expression of epigenetic modifiers is not significantly altered by exposure to secondhand smoke. Lung Cancer. 2015;90:598–603. doi: 10.1016/j.lungcan.2015.10.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Tommasi S., Zheng A., Weninger A., Bates S.E., Li X.A., Wu X., Hollstein M., Besaratinia A. Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic Acids Res. 2013;41:182–195. doi: 10.1093/nar/gks1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44–57. doi: 10.1038/nprot.2008.211. [DOI] [PubMed] [Google Scholar]
- 69.Mehlem A., Hagberg C.E., Muhl L., Eriksson U., Falkevall A. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat. Protoc. 2013;8:1149–1154. doi: 10.1038/nprot.2013.055. [DOI] [PubMed] [Google Scholar]
- 70.Krishna M. Role of special stains in diagnostic liver pathology. Clin. Liver Dis. (Hoboken) 2013;2:S8–S10. doi: 10.1002/cld.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Cardiff R.D., Miller C.H., Munn R.J. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb. Protoc. 2014;2014:655–658. doi: 10.1101/pdb.prot073411. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.